Mauro Ariel Castro Sayat

Dr. Mauro Ariel Castro Sayat

Respiratory Intermediate Care Unit, Hospital Fernández, Buenos Aires, Argentina
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2022 in Pulmonology
Verified
Journal Article
Open access
MVMaría Laura Vega
María Laura Vega
RDRoberto Dongilli
Roberto Dongilli
GOGustavo Olaizola
Gustavo Olaizola
NCNicolás Colaianni
Nicolás Colaianni
Mauro Ariel Castro SayatMauro Ariel Castro Sayat
Mauro Ariel Castro Sayat
stefano navastefano nava
stefano nava
High flow nasal cannula (HFNC) is used to treat acute hypoxemic respiratory failure (AHRF) even outside the ICU and the ROX index (pulse oximetry/fraction of inspired oxygen/respiratory rate) may predict HFNC failure. The purpose of this investigation was therefore to verify whether the ROX index is an accurate predictor of HFNC failure for COVID-19 patients treated outside the intensive care unit (ICU) and to evaluate the validity of the previously suggested threshold. Multicenter study. Retrospective observational analysis of prospectively collected data. 3 centres specialized in non-invasive respiratory support (Buenos Aires, Argentina; Bolzano and Treviso, Italy). Patients treated outside the ICU were analysed The variables to calculate the ROX index were collected during the first day of therapy at 2, 6, 12 and 24 hours and then recorded every 24 hours. HFNC failure was defined as escalation of respiratory support to invasive mechanical ventilation (IMV) or death. A total of 35 (29%) patients failed HFNC and required intubation. ROC analysis identified the 12-hour ROX index as the best predictor of intubation with an AUC of 0.7916[CI 95% 0.6905-0.8927] and the best threshold to be 5.99[Specificity 96% Sensitivity 62%]. In the survival analysis, a ROX value <5.99 was associated with an increased risk of failure (p = 0008 log – rank test). The threshold of 4,9 identified by Roca as the best predictor in non-COVID patients, was not able to discriminate between success and failure (p = 0.4 log-rank test) in our patients. ROX index may be useful in guiding the clinicians in their decision to intubate patients, especially in patients with moderate ARF, treated therefore outside the ICU. Indeed, it also demonstrates a different threshold value than reported for non-COVID patients, possibly related to the different mechanisms of hypoxia.

21 July 2021 in Respiratory Care
Verified
Journal Article
Closed access
PDF file
Nicolás Colaianni-AlfonsoNicolás Colaianni-Alfonso
Nicolás Colaianni-Alfonso
GMGuillermo Montiel
Guillermo Montiel
Mauro Ariel Castro SayatMauro Ariel Castro Sayat
Mauro Ariel Castro Sayat
CSCatalina Siroti
Catalina Siroti
MVMaria Laura Vega
Maria Laura Vega
JAJosé Miguel Alonso-Íñigo
José Miguel Alonso-Íñigo
BACKGROUND: The roles of high-flow nasal cannula (HFNC) and CPAP in coronavirus disease 2019 (COVID-19) are controversial. The objective of the study was to evaluate the impact of the application of a noninvasive respiratory support algorithm on clinical outcomes in subjects with COVID-19 and with acute respiratory failure. METHODS: We performed a single-center prospective observational study of subjects with respiratory failure from COVID-19 managed with HFNC and with CPAP plus HFNC (combined therapy). The main outcome was the intubation rate, which defined failure of therapy. We also analyzed the role of the ROX index ([ S pO 2 / F IO 2 ]/breathing frequency) to predict the need for intubation. RESULTS: From June to December 2020, 113 subjects with COVID-19 respiratory failure were admitted to our respiratory intermediate care unit. HFNC was applied in 65 subjects (57.52%) and combined therapy in 48 subjects (42.47%). A total of 83 subjects (73.45%) were successfully treated with noninvasive respiratory support. The intubation rate was 26.54%, and the overall mortality rate was 14.15%. The mortality rate in subjects who were intubated was 55.2%. An ROX index of 6.28 at 12 h predicted noninvasive respiratory support failure, with 97.6% sensitivity and 51.8% specificity. CONCLUSIONS: Data from our cohort managed in a respiratory intermediate care unit showed that combined noninvasive respiratory support was feasible, with favorable outcomes. Further prospective studies are required.

30 September 2021 in Pulmonology
Verified
Journal Article
Open access
MVM.L. Vega
M.L. Vega
RDR. Dongilli
R. Dongilli
GOG. Olaizola
G. Olaizola
NCN. Colaianni
N. Colaianni
Mauro Ariel Castro SayatMauro Ariel Castro Sayat
Mauro Ariel Castro Sayat
stefano navastefano nava
stefano nava

21 October 2022 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
NCNicolás Colaianni-Alfonso
Nicolás Colaianni-Alfonso
GMGuillermo Cesar Montiel
Guillermo Cesar Montiel
Mauro Ariel Castro SayatMauro Ariel Castro Sayat
Mauro Ariel Castro Sayat
OROriol Roca
Oriol Roca
DGDomenico Luca Grieco
Domenico Luca Grieco

11 April 2023 in Respiratory Care
Verified
Journal Article
Closed access
PDF file
Nicolás Colaianni-AlfonsoNicolás Colaianni-Alfonso
Nicolás Colaianni-Alfonso
RMRonan MacLoughlin
Ronan MacLoughlin
AEAriel Espada
Ariel Espada
YSYasmine Saa
Yasmine Saa
MTMariano Techera
Mariano Techera
Mauro Ariel Castro SayatMauro Ariel Castro Sayat
Mauro Ariel Castro Sayat
BACKGROUND: Bronchodilator delivery via a high-flow nasal cannula (HFNC) has generated interest in recent years. The efficacy of in-line vibrating mesh nebulizers with an HFNC during COPD exacerbation is limited. The aim of this study was to evaluate the clinical response of subjects with COPD exacerbation who require bronchodilator therapy (anticholinergic and β-agonist) by using a vibrating mesh nebulizer in line with an HFNC. METHODS: This was a prospective single-center study performed in a respiratory intermediate care unit that enrolled patients with a diagnosis of COPD exacerbation who required noninvasive ventilation on admission. All the subjects underwent noninvasive ventilation breaks with an HFNC. After clinical stability, pulmonary function tests were performed to assess changes in FEV 1 and clinical parameters before and after bronchodilation by using a vibrating mesh nebulizer in line with an HFNC. RESULTS: Forty-six patients with COPD exacerbation were admitted. Five patients who did not use noninvasive ventilation and 10 patients who did not receive bronchodilator treatment with a vibrating mesh nebulizer were excluded. Thirty-one were selected, but 1 subject was secondarily excluded due to loss of data. Finally, 30 subjects were included. The primary outcome was spirometric changes in FEV 1 . The mean ± SD FEV 1 before receiving bronchodilator treatment by using a vibrating mesh nebulizer in line with an HFNC was 0.74 ± 0.10 L, and, after receiving treatment, the mean ± SD FEV 1 changed to 0.88 ± 0.12 L ( P < .001). Similarly, the mean ± SD FVC increased from 1.75 ± 0.54 L to 2.13 ± 0.63 L ( P < .001). Considerable differences were observed in breathing frequency and heart rate after receiving bronchodilator treatment. No relevant changes were observed in the Borg scale or S p O 2 after treatment. The mean clinical stability recorded was 4 d. CONCLUSIONS: In subjects with COPD exacerbation, bronchodilator treatment by using a vibrating mesh nebulizer in line with an HFNC showed a mild but significant improvement in FEV 1 and FVC. In addition, a decrease in breathing frequency was observed, suggesting a reduction in dynamic hyperinflation.

8 March 2024 in The Ultrasound Journal
Verified
Journal Article
Open access
PDF file
Mauro Ariel Castro SayatMauro Ariel Castro Sayat
Mauro Ariel Castro Sayat
Nicolás Colaianni-AlfonsoNicolás Colaianni-Alfonso
Nicolás Colaianni-Alfonso
LVLuigi Vetrugno
Luigi Vetrugno
GOGustavo Olaizola
Gustavo Olaizola
CBCristian Benay
Cristian Benay
CSCatalina Siroti
Catalina Siroti
Background: Lung ultrasound has demonstrated its usefulness in several respiratory diseases management. One derived score, the Lung Ultrasound (LUS) score, is considered a good outcome predictor in patients with Acute Respiratory Failure (ARF). Nevertheless, it has not been tested in patients undergoing non-invasive respiratory support (NIRS). Taking this into account, the aim of this study is to evaluate LUS score as a predictor of 90-day mortality, ETI (Endotracheal intubation) and HFNC (High Flow Nasal Cannula) failure in patients with ARF due to COVID-19 admitted to a Respiratory Intermediate Care Unit (RICU) for NIRS management. Results: One hundred one patients were admitted to the RICU during the study period. Among these 76% were males and the median age was 55 (45–64) years. Initial ARF management started with HFNC, the next step was the use of Continuous Positive Airway Pressure (CPAP) devices and the last intervention was ETI and Intensive Care Unit (ICU) admission. Of the total study population, CPAP was required in 40%, ETI in 26%, while 15% died. By means of a ROC analysis, a LUS ≥ 25 points was identified as the cut-off point for mortality(AUC 0.81, OR 1.40, 95% CI 1.14 to 1.71; p < 0.001), ETI (AUC 0.83, OR 1.43, 95% CI 1.20 to 1.70; p < 0.001) and HFNC failure (AUC 0.75, OR 1.25, 95% CI 1.12 to 1.41; p < 0.001). Kaplan-Meier survival curves also identified LUS ≥ 25 as a predictor of 90-days mortality (HR 4.16, 95% CI 1.27–13.6) and 30 days ETI as well. Conclusion: In our study, a ≥ 25 point cut-off of the Lung Ultrasound Score was identified as a good outcome prediction factor for 90-days mortality, ETI and HFNC failure in a COVID-19 ARF patients cohort treated in a RICU. Considering that LUS score is easy to calculate, a multicenter study to confirm our findings should be performed.